40 Guest Street
About Sherlock BioSciences
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate diagnostic tests that empower individuals to control their own healthcare. We are creating a new generation of CRISPR and Synthetic Biology-based molecular diagnostic technology platforms that can rapidly deliver accurate and inexpensive results in any setting. We envision a world where Sherlock’s products will enable users to make more effective decisions in any environment, including hospitals, industrial settings, low-resource settings, and at-home. Successful candidates will join an exciting, collaborative, and fast-paced company that seeks to disrupt diagnostics and change the trajectory of human health.
6 articles with Sherlock BioSciences
Sherlock Biosciences today announced that it has received additional funding from the Bill & Melinda Gates Foundation to advance its rapid, instrument-free molecular diagnostic testing platform.
Sherlock Biosciences and Tolo Biotech Expand Collaboration to Advance Development and Adoption of CRISPR-based Diagnostics
Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has signed a licensing agreement with Shanghai-based Tolo Biotech.
The 221b Foundation, a non-profit founded by Sherlock Biosciences to bring novel CRISPR-based diagnostics to underserved populations around the world, today announced that Dr. Pardis Sabeti has joined its Board of Directors.
Company Continues to Grow Leadership Team to Advance the Future of Molecular Diagnostics.
Sherlock Biosciences today announced that industry veteran Karen Davies has been appointed to its executive team as Chief Development Officer.
Bryan Dechairo, newly appointed president and CEO of Sherlock Biosciences, learned early to fill gaps and seize opportunities. Read more about his views.